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INTRODUCTION
Anemia is a very common complication in chronic 
kidney disease (CKD) patients, resulting in fatigue, 
reduced quality of life, shortness of breath and de-
creased exercise capacity (1-3). Multiple factors are 
involved in the pathogenesis of anemia in CKD: iron 
defi ciency, inadequate production of erythropoietin 
(Epo), hepcidin and hypoxia-inducible factors (HIFs) 
(2). Infl ammation and oxidative stress are present in 
patients with CKD and produce a state of functional 
iron defi ciency (2). Reduced oxygen delivery activates 
hypoxia-inducible factors (HIFs) leading to increased 
transcription of genes, in turn leading to Epo synthe-
sis. Epo binds to the Epo receptor expressed on eryth-
roid progenitor cells, inhibiting apoptosis and enhanc-
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ing the population of circulating red blood cells (2). 
Th e cellular oxygen sensing is by a family of prolyl 
hydroxylases (PHDs) and their role is regulating HIFs. 
PHDs inhibitors serve as HIF stabilizers, and are cur-
rently investigated in clinical trials for the treatment 
of anemia in CKD (2). Anemia is mainly due to iron 
defi ciency and inadequate renal production of eryth-
ropoietin (4). Other factors include elevated hepci-
din levels in chronic infl ammation state (as in CKD 
patients) removing non-transferrin bound iron from 
the circulation by iron trapping in macrophages (5). 
Hepcidin is produced by the liver in response to a 
number of factors including body iron status and in-
fl ammatory cytokines, and binds to ferroportin on the 
basolateral surface of gut enterocytes, and inhibiting 
absorption of iron from the gut lumen (5). Iron defi -
ciency is one of the leading risk factors for disability 
and death and is the most prevalent nutritional disor-
der worldwide (6). Iron defi ciency is a very important 
clinical concern in CKD patients (7). Th is problem 
gives rise to iron defi ciency anemia and various im-
paired cellular functions (8). Oral supplementation, in 
particular with ferrous salts, is associated with a high 
rate of gastrointestinal side eff ects and is poorly ab-
sorbed (9). Th is problem is avoided with intravenous 
(iv.) iron. Iron defi ciency is one of the most important 
causes of erythropoietin hyporesponsiveness. Eryth-
ropoiesis stimulating agents (ESAs) are today the main 
treatment for CKD patients with anemia (1). ESAs are 
eff ective in correcting and maintaining hemoglobin 
(Hb) levels and decreasing the need for blood trans-
fusions. Partial correction treatment of anemia with 
ESAs is expensive, and full correction of Hb is not 
recommended (10). Before 1989 and the introduction 
of ESAs for anemia of CKD, repeated transfusions 
given to patients caused iron overload (2). Aft er the 
introduction of ESAs, supplemental iron optimiz-
es hemoglobin response and allows reduction of the 
ESA dose. Because of economic reasons and concerns 
about ESA safety, more questions were open (10). Pro-
spective randomized controlled trials in patients with 
CKD not on dialysis (stages 3 to 5; CHOIR, CREATE 
and TREAT studies) did not demonstrate the expect-
ed benefi cial eff ects of correcting anemia, but sug-
gested an increased risk of death and cardiovascular 
(CV) events when targeting higher Hb levels (≥13 g/
dL) (11,12). Additional analyses suggest that the risk 
of death or CV events appears to be highest in CKD 
patients who fail to respond to ESAs, as indicated by 
lower achieved Hb levels and higher average ESA dose 
requirements and have led to changes in prescribing 
information and practice guidelines (10-12).
Iron supplementation is more effi  cacious via intrave-
nous (more adherence) compared to oral administra-
tion and the use of intravenous iron has escalated in 
recent years (2). Th e safety of iron compounds is ques-
tionable due to their potential to induce iron overload, 
oxidative stress, hypersensitivity reactions, and per-
missive environment for infectious processes (2). In 
this prospective observational study, we compared the 
effi  cacy and safety profi le of oral and intravenous iron 
with erythropoietin for the treatment of iron defi cien-
cy anemia in 43 non dialysis patients (ND-CKD) with 
the confi rmed diagnosis of iron defi ciency anemia (A) 
at Merkur University Hospital. We compared the ben-
efi ts and risks of oral and parenteral iron, in order to 
provide strategies for its optimal use due to the risk for 
adverse eff ects. 
PATIENTS AND METHODS 
Patients 
Th e study protocol included nonpregnant female and 
male patients with ND-CKD and anemia. Patients 
were aged 18-85 years, mean age 68.5 years and base-
line proteinuria 0.64 g/24 h.
Exclusion criteria were patients on hemodialysis, peri-
toneal dialysis or patients with kidney transplantation, 
heart failure patients, history of secondary hyperpara-
thyroidism, history of gastrointestinal bleeding, sign 
of infl ammation (measured with C-reactive protein 
(CRP) or hsCRP >5 mg/L), patients taking drugs such 
as cyclophosphamide, mycophenolate mofetil, angio-
tensin-converting inhibitors or angiotensin receptor 
blockers (medicines that suppress Epo production), 
patients with malignancy (such as myeloma), history 
of thromboembolism and uncontrolled resistant hy-
pertension (confi rmed diastolic blood pressure >90 
mm Hg or systolic blood pressure >140 mm Hg with-
out offi  ce blood pressure measurements to exclude 
white coat hypertension, common in patients with 
CKD). Th e largest number of patients (n=40; 93%) had 
two or more accompanying diseases such as hyperten-
sion, metabolic syndrome or controlled diabetes type 
2, hypothyroidism and atherosclerosis. Patients took 
4-8 medications daily: antihypertensive drugs (3 or 
more, such as calcium channel blockers, beta blockers 
such as nebivolol or bisoprolol, moksonidine, urapidil, 
diuretics such as HCTZ or indapamide), drugs for dia-
betes and gastric protection (proton pump inhibitors 
20 mg), hypothyroidism therapy (levothyroxine doses 
25-50 mg) and antilipemic drugs. Laboratory values 
were measured by standardized methods and Chronic 
Kidney Disease Epidemiology Collaboration (CKD-
EPI) was used for estimating GFR categories of CKD. 
Home blood pressure measurement normal showed 
blood pressure value, controlled resistant hyperten-
sion (<140/90 mm Hg), while offi  ce blood pressure 
measurements showed stage I hypertension in 70% of 
patients (140/90-159/99 mm Hg).
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Patients were divided into group A (n=20) receiving 
intravenous iron sucrose (10 patients, 5F/5M, infusion 
of 10 mL/200 mg elemental iron, diluted in 250 mL so-
dium chloride 0.9%, during 60 minutes administered 
on day 1, day 10, day 20, day 30, day 45 to give a cumu-
lative dose of 1000 mg within a 45-day period) or ferric 
carboxymaltose (10 patients, 7F/3M) in doses of 1000 
mg once /30-45 min infusion every 45 days. Clinical 
follow-up aft er the infusion for at least 30 minutes was 
mandatory. In group B (n=23, 10M/13F), oral daily 
intake of iron (ferrous fumarate 350 mg) was adminis-
tered. Erythropoietin beta subcutaneously in doses of 
4000-6000 IU every week during the correction phase 
of anemia treatment was given. Iron supplementation 
was administered in order to achieve serum ferritin 
and transferrin saturation (TSAT) in accordance with 
ERBP and KDIGO guidelines (11,12). In all patients, 
TSAT was >10% at the beginning. Hemoglobin (Hb) 
was checked at the beginning and every 45 days (to 
monitor Hb fl uctuatins) and aft er 12 months in both 
groups. All patients took vitamin B12 (500 mg) im. 
once a month and folate acid (oral, 5 mg/day) to pre-
vent defi ciency due to poor dietary intake. 
Table 1. 









Month 1 9. 45±0.88 8.8±0.29 21±10.5 151±111 19.36
Month 12 10.53±1.09 9.82±0.35 27±11.2 285±208 23.14
Hb = hemoglobin value (g/dL), Fe= iron (μmol/L), TSAT = transferrin 
saturation (%). eGFR = glomerular fi ltration rate (CKD-EPI formula, 
mL/min/1.73m2), Values are expressed as mean ± standard deviation 
(SD). Other data are presented as number. 
Th ere were no diff erences between the groups in body 
mass index, race, social status and education. Th e 
study was conducted in accordance with the amend-
ed Declaration of Helsinki. Th e study was approved 
by the hospital Ethics Committee and all participants 
gave their informed written consent.
Statistical analysis
Data were processed by use of the SPSS soft ware. Sta-
tistical data analysis was performed using descriptive 
statistics. Continuous variables were presented as 
mean with standard deviation. Categorical variables 
were presented as percentage. Paired sample t-test was 
applied for comparison of results. Th e level of statisti-
cal signifi cance was set at p<0.001.
RESULTS 
Th is study carried out in a cohort of 43 ND-CKD 
patients showed that 58.1% of patients were female 
(F=25). Th e majority of patients were in the >50 age 
group (62%). Primary endpoint was to evaluate the 
effi  cacy and safety of small doses of ESA and iron 
therapy in ND-CKD patients. Th ere were no statis-
tically signifi cant diff erences in Hb values between 
the groups of patients stratifi ed according to prima-
ry kidney disease (hypertensive nephropathy in 40%, 
diabetic kidney disease in 25%, glomerulonephritis in 
11% and chronic pyelonephritis in 24% of patients), 
age and sex. Th e mean level of iron at the beginning 
was 8.8±0.29 umol/L (male/female 9.7/7.9±0.28/0.31 
μmol/L) and aft er 12 months 9.82±0.35 umol/L 
(M/F 10.7/8.94± 0.27/0.43 μmol/L). Before starting 
the study, the mean TSAT was 2±10.5% and aft er 12 
months 27±11.2%. Th e mean ferritin level at the begin-
ning was 151±111 and at the end of the study 285±208 
ng/mL. In the treatment groups, the mean Hb level at 
the beginning was 9.45±0.88 (9.19±0.84 g/dL in group 
A and 9.72±0.95 g/dL in group B. Aft er 12 months, the 
mean Hb was 10.53±1.09 (10.65±0.97 g/dL in group 
A and 10.42±1.22 g/dL in group B). Th ere was minor 
variability in Hb levels in controls and our study found 
Hb fl uctuations 0.6 g/dL-1.15 g/dL above the starting 
Hb values in both groups of patients. Iron doses and 
ESA were stable at the mean TSAT (>20%) and fer-
ritin (>200 ng/mL) levels in the majority of patients 
(82%). Doses were decreased if TSAT was increased 
>30% or ferritin levels were >500 ng/mL (18%). If we 
compare results before and aft er 12 months of ther-
apy, there was a diff erence (p<0.001). If we compare 
the groups on parenteral or peroral iron therapy, there 
was no diff erence in effi  cacy. Th e majority of patients 
reported better exercise tolerance (96%) and sleep 
(65%). During the study, none of the patients had hy-
pertensive urgency or emergency. None of the patients 
had acute reactions or skin adverse eff ects to ferric 
carboxymaltose or iron sucrose. If we compare the 
groups according to safety, there were no diff erences 
between parenteral iron therapy with ferric carboxy-
maltose and iron sucrose. Secondary endpoint of this 
study was evaluation of anemia therapy for improve-
ment of kidney function. Most patients were within 
CKD stage 3b or 4 (90%). Baseline eGFR CKD-EPI 
values were 19.36 mL/min/1.73m2 (19.31 in group A 
and 19.42 in group B (range 16.8-45.6)) vs. 23.14 mL/
min/1.73m2 (23.17 in group A and 23.11 in group B 
(range 17.3-46.8 mL/min/1.73m2) aft er 12 months and 
proven to improve renal function compared to base-
line, but statistically signifi cant diff erences between 
groups A and B were not found. During the study, two 
patients started dialysis treatment.
Clinical follow-up aft er 6 months revealed the follow-
ing: two male patients started dialysis aft er predialysis 
education; two female patients and one male patient 
had urinary tract infections; one female patient had 
pneumonia infection (no hospitalization); one patient 
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had transient ischemic attack (no hospitalization); 
four patients had atrial fi brillation; two patients had 
uncontrolled resistant hypertension (no hospitaliza-
tion); and worsening of kidney function due to con-
trast nephropathy (one hospitalization).
DISCUSSION 
According to the last guidelines, when transferrin sat-
uration is lower than 30% and ferritin lower than 500 
ng/mL, iron therapy should be started to avoid or to re-
duce the doses of ESAs needed to treat anemia in CKD 
patients (2,11). Th e risks associated with ESAs, includ-
ing an increased risk of death and CV events, highlight 
the need for additional therapies that might minimize 
or avoid these risks when compared to currently avail-
able ESAs. Th erefore, the unmet medical need for the 
treatment of anemia in non-dialysis dependent CKD 
(NDD-CKD) patients remains high, especially from 
a CV safety perspective. Supplementation of iron is 
recommended for all non-dialysis and dialysis CKD 
patients with iron-defi ciency anemia and those who 
receive erythropoiesis-stimulating agents (11).
All iron products should be prescribed, administered 
orally or injected (at hospital) and the most stable in-
travenous iron complexes (low molecular weight iron 
dextran, ferric carboxymaltose, and iron isomaltoside 
1000 mg) can be given in higher single doses and more 
rapidly than preparations such as iron sucrose. Test 
doses are no more mandatory for conventional low 
molecular weight (LMW) iron dextrans. In the ND-
CKD population, the erythropoietic response is also 
signifi cantly higher using intravenous versus oral iron, 
and tolerability is good (12). Intravenous iron supple-
mentation might avoid or at least delay the need for 
erythropoiesis-stimulating agents and the need for 
dialysis (12). Pre-dialyzed patients today in Croatia 
can aff ord the treatment with ESA. Th e guidelines 
provided by KDIGO for ESA treatment in ND-CKD 
and CKD patients on dialysis recommended Hb target 
from 9.5 to 11.5 g/dL and should not exceed 12 g/dL, 
and European guidelines recommend Hb target levels 
of 10 to 12 g/dL (11,12). Today, we have the ability to 
achieve iron stores replenishment correctly in dialy-
sis dependent and non-dialysis dependent CKD pa-
tients without compromising safety (13). But the risks 
of the increased iron use to treat CKD anemia, iron 
overload/toxicity through excess iron deposition and 
induction of oxidative stress, increased risk of infec-
tions, or mortality are open questions with this ther-
apy (14,15). 
In our study, there was no anaphylaxis or adverse 
events encountered during administration of ferric 
carboxymaltose or iron sucrose. Th ere was no sign 
of iron overdosing, heart failure or mortality, but we 
excluded patients with secondary hyperparathyroid-
ism (a recognized cause of resistance to ESAs. High 
phosphorus levels have been shown to increase fi bro-
blast growth factor 23 levels, which is associated with 
klotho suppression and low klotho levels cause defi -
ciency in activated vitamin D, and vitamin D defi cien-
cy has been implicated in the development of anemia), 
patients with gastrointestinal bleeding (from medical 
records to prevent iron AE) or patients with any sign of 
infl ammation (elevation of hsCRP), as well as patients 
with heart failure. In our study, iron defi ciency was de-
fi ned based on a combination of two commonly used 
markers, ferritin and transferrin saturation (TSAT) 
(16,17). Eisenga et al. have shown that of the tradition-
ally used markers of iron status, reduced TSAT <10% 
is most strongly associated with the risk of adverse 
outcomes (cardiovascular mortality) in CKD patients 
irrespective of serum ferritin level (4). 
A study by Lee et al. showed that TSAT was associated 
with less severe anemia in early CKD patients. Serum 
hepcidin was associated with more severe anemia in 
advanced CKD patients (18). Cardiovascular disease 
is a common complication in patients with CKD. One 
of the most important functions of the cardiovascu-
lar system is oxygen delivery, therefore cardiovascular 
disease is linked to insuffi  cient tissue oxygenation; the 
cellular oxygen sensing by a family of prolyl hydroxy-
lases (PHDs) and their role in regulating hypoxia-in-
ducible factors (HIFs) in the future will give new data 
on PHD inhibition and impact on anemia in CKD (2).
Neutrophil gelatinase-associated lipocalin (NGAL), a 
biomarker of acute kidney injury, is known to be as-
sociated with iron metabolism. A new study showed 
that plasma NGAL (best cut-off  value ≤394  ng/mL) 
was superior to serum ferritin (suggested cut-off  val-
ue ≤500 ng/mL) in both sensitivity and specifi city and 
was associated with iron status in anemic patients with 
predialysis CKD (19). Data in our study showed an ad-
ditional eff ect of anemia treatment in slowing natural 
progression of CKD. In the majority of patients, Hb 
levels were within the acceptable target range accord-
ing to the last European and Croatian guidelines and 
studies (12,16,17). In contrast to managing patients 
on hemodialysis in whom iron strategies are more fo-
cused on intravenous iron, ND-CKD patients may re-
ceive either oral or intravenous iron (20). Th e health-
care, social care, and economic costs of CKD patients 
are a growing problem. Any interventional program to 
decline progression to end stage renal disease (ESRD) 
is very important as indicated by the fact that patients 
with ESRD make up less than 1% of Medicare patients 
in USA but the cost of their care accounts for more 
than 5% of the Medicare total budget (21). 
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In ND-CKD patients, anemia can be successfully 
treated by small doses of ESA and by oral or intra-
venous iron (ferric carboxymaltose or iron sucrose) 
supplementation in order to reduce cardiovascular 
risk and kidney failure progression. In this study, we 
performed home blood pressure measurement to im-
prove adherence to medication in ND-CKD patients 
and to exclude WCH (22). Our aim was to exclude 
Epo-induced hypertension and none of the patients 
had hypertensive urgency or emergency during the 
study.
Further investigations should be conducted to analyze 
the implications of new drugs to treat anemia in CKD 
patients. 
LIMITATIONS OF THE STUDY
Th e main limitation of this study was its observational 
nature. Another limitation was that we had no data on 
serum albumin levels to conclude about malnutrition.
CONCLUSIONS 
Parenteral or oral iron in combination with Epo is 
eff ective treatment of anemia in ND-CKD patients if 
other factors are considered. Oral or intravenous iron 
supplements are an important adjunct in the treat-
ment of anemia in patients with CKD. In the future, 
we will have new drugs such as hepcidin antagonists, 
HIF and ferroportin stabilizers in order to delay CKD 
progression. Th is alternative therapeutic approach in 
the future may avoid the overshoots and fl uctuations 
in Hb levels seen with currently injectable ESAs in 
ESRD and provide a steady and controlled rise in Hb 
concentration. 
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Kamen temeljac liječenja anemije kronične bubrežne bolesti (KBB) danas čini primjena eritropoietina uz liječenje prepa-
ratima željeza. Anemija KBB je multifaktorska, a najčešće uključuje poremećaj željeza (apsolutni ili funkcionalni manjak), 
nedostatnu proizvodnju eritropoietina, a u poslijednjih nekoliko godina sve više se navode i povišeni hepcidin i čimbenici 
indukcije hipoksije (hypoxia-inducible factor, HIF). U budućnosti najviše obećava primjena stabilizatora HIF-a koji stimulira-
ju eritropoezu endogenim putem, reguliraju metabolizam željeza te interakciju s hepcidinom, no još uvijek su u fazi istraži-
vanja i nedostupni. Bolesnici s KBB imaju značajne dodatne čimbenike koji mogu doprinijeti rezistenciji u liječenju anemije 
kronične bubrežne bolesti. Cilj studije bio je utvrditi učinkovitost i sigurnost primjene liječenja željezom uz niske doze 
eritropoetinske terapije u predijaliznoj fazi ako su isključeni čimbenici koji mogu doprinijeti rezistenciji u liječenju anemije 
KBB-a. U neintervencijskoj, prospektivnoj opservacijskoj studiji ispitan je utjecaj primjene eritropoietina beta (supkutano, 
jednom tjedno u dozi 4000-6000 IJ) u kombinaciji s peroralnom ili parenteralnom primjenom željeza u 43 bolesnika u fazi 
predijalize, a koji nisu liječeni ranije dijalizom ili transplantacijom, bez sekundarnog hiperparatireoidizma ili srčanog popu-
štanja, anamneze tromboembolizma i zloćudne bolesti, neregulirane rezistentne hipertenzije, gastrointestinalnog krvarenja, 
koji nisu liječeni lijekovima poput ciklofosfamida, mikofenolatmofetila, blokatorima renin angiotenzin sustava. Bolesnici su 
podijeljeni u dvije skupine prema načinu primjene željeza (parenteralno, 2 oblika u dozi 1000 mg tijekom 45 dana ili pero-
ralno, željezo fumarat 350 mg svaki dan) kako bi se postigla razina feritina od 200-500 mg/L i TSAT >20%. Srednja razina 
vrijednosti željeza na početku iznosila je u M/F 9,7/7,9±0,28/0,31, dok je na kraju studije bila 10,7/8,94±0,27/0,43 μmol/L. 
Razina hemoglobina (Hb) je na početku iznosila 9,19±0,84 g/dL (skupina A) i 9,72±0,95 g/dL (skupina B). Na kraju praćenja 
došlo je u obje skupine do porasta razine Hb u odnosu na početne vrijednosti: 10,65±0,97 g/dL (skupina A) i 10,42±1,22 g/
dL (skupina B) (p<0,001), no između skupina A i B nije utvrđena statistički značajna razlika. Rezultati studije pokazuju da 
je liječenje anemije KBB postojećim dostupnim lijekovima učinkovito u slučaju isključenja čimbenika koji mogu doprinijeti 
rezistenciji na liječenje. Kako najveći broj bolesnika s KBB ima postojeće čimbenike koji doprinose rezistenciji liječenja 
anemije KBB-a, u budućnosti najviše obećava primjena stabilizatora HIF-a.
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